Harvard Pilgrim Health CareMedicaid · Coverage · Provider Newsletter · MA · Rheumatology, Gastroenterology, DermatologyHigh impact
Reminder: preferred biosimilars to Humira and Stelara
Act
by Mar 31, 2026
Effective date
Jan 5, 2026
Identified
Jun 20, 2026
Summary
MassHealth is transitioning from Humira and Stelara to preferred biosimilars effective January 5, 2026, with a grace period through March 31, 2026. After April 1, 2026, Humira and Stelara will require step therapy (trying preferred biosimilars first) and new prior authorizations for patients who haven't switched.
Get alerts when payers change rules like this one
We check Harvard Pilgrim Health Care and other payers every day and email you when a change matches your specialty and state.
01Billing team must identify all patients on Humira and Stelara and coordinate with providers to transition them to preferred biosimilars (Hadlima, adalimumab-adaz for Humira; Pyzchiva, Imuldosa, or Steqeyma for Stelara).
02Update prior authorization workflows in billing system for April 1, 2026 to require step therapy documentation for Humira/Stelara requests.
03Note that Imuldosa requires new prescriptions while others can be pharmacy-substituted.
Original notice
Reminder: preferred biosimilars to Humira and Stelara
point32health.org · Always check the source before changing claims.
Summaries are AI-assisted. Always confirm against the original payer notice.
What is PolicyChanges
One workspace for payer rules, prior auth, coding and compliance
Medical practices use PolicyChanges to catch payer changes before they cause denials. Every change is summarized in plain English, with the codes involved, the date it takes effect and what to do.